Tools
Register Login

biolyon.com

YOUAH Home » more biotech news » Analysts experts are dazzled by the blockbuster potential of Novartis LCZ696
Friday, 20 Oct 2017

Analysts experts are dazzled by the blockbuster potential of Novartis LCZ696

The data aren't out yet, but the buzz about Novartis' new late-stage contender for blockbuster status is growing to fever pitch. This morning Leerink opted to add on $3 billion to the pharma giant's forecasted revenue for 2026, concluding that LCZ696 has the distinct potential of becoming a mainstay therapy in the prevention of cardiovascular deaths--even substituting for the generic ACE inhibitors that now dominate the market.

Read more: Analysts experts are dazzled by the blockbuster potential of Novartis LCZ696

social

FacebookTwitterDiggDeliciousStumbleuponGoogle BookmarksRedditNewsvineTechnoratiLinkedinMixx